Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide with Maintenance Avelumab for Metastatic Urothelial Cancer
NCT06018116Phase 2Withdrawn
- Sponsor
- CHU de Québec-Université Laval
- Start
- Nov 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bicalutamide in urothelial carcinoma (UC), sponsored by CHU de Québec-Université Laval. Planned start Nov 2023; status: withdrawn.
02
Drugs
bicalutamide
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06018116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06018116.